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Alzheimer’s disease (AD) is a neurodegenerative disorder with clinical manifestations of 
progressive memory decline and loss of executive function and language. AD affects 
an estimated 5.3 million Americans alone and is the most common form of age-related 
dementia with a rapidly growing prevalence among the aging population—those 65 years 
of age or older. AD is characterized by accumulation of aggregated amyloid-beta (Aβ) 
in the brain, which leads to one of the pathological hallmarks of AD—Aβ plaques. As a 
result, Aβ plaques have been extensively studied after being first described over a cen-
tury ago. Advances in brain imaging and quantitative measures of Aβ in biological fluids 
have yielded insight into the time course of plaque development decades before and 
after AD symptom onset. However, despite the fundamental role of Aβ plaques in AD, 
in vivo measures of individual plaque growth, growth distribution, and dynamics are still 
lacking. To address this question, we combined stable isotope labeling kinetics (SILK) 
and nanoscale secondary ion mass spectrometry (NanoSIMS) imaging in an approach 
termed SILK–SIMS to resolve plaque dynamics in three human AD brains. In human AD 
brain, plaques exhibit incorporation of a stable isotope tracer. Tracer enrichment was 
highly variable between plaques and the spatial distribution asymmetric with both quies-
cent and active nanometer sub-regions of tracer incorporation. These data reveal that Aβ 
plaques are dynamic structures with deposition rates over days indicating a highly active 
process. Here, we report the first, direct quantitative measures of in vivo deposition into 
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plaques in human AD brain. Our SILK–SIMS studies will provide invaluable information 
on plaque dynamics in the normal and diseased brain and offer many new avenues for 
investigation into pathological mechanisms of the disease, with implications for thera-
peutic development.
Keywords: alzheimer’s disease, aβ plaques, plaque dynamics, stable isotope tracer, silK–siMs
inTrODUcTiOn
Alzheimer’s disease (AD) is a devastating neurodegenerative 
disorder characterized by progressive cognitive and functional 
decline and is the most common form of age-related dementia 
(1, 2). The incidence of AD-related death and disability is rapidly 
growing in persons 65 years of age or older whose risk of develop-
ing the disease doubles every 5 years (3); currently, an estimated 
5.3 million Americans are affected (4). Amyloid-beta (Aβ), a 
38–43 amino acid peptide derived from the proteolytic cleavage of 
the amyloid precursor protein, is implicated as a pathogenic spe-
cies in AD (5–10). Abnormal accumulation and aggregation of Aβ 
in the cerebral extracellular space result in one of the pathological 
hallmarks of AD—amyloid plaques. As a result, the onset and rate 
of amyloidosis has been intensively studied over the past several 
decades. Although older individuals may have extensive Aβ depo-
sition without clinical signs of dementia (11–14), there is a strong 
association of amyloid plaques with AD dementia. Longitudinal 
measures of amyloid pathology have shown increases in amyloid 
deposition 15–20  years prior to dementia onset (15) in early 
onset, familial AD and predict future cognitive decline (16–20).
As amyloid pathology increases in vivo, a concomitant decline 
in cerebrospinal fluid (CSF) Aβ42 occurs (21). More recent stud-
ies in the production and clearance of Aβ in CSF (22) demon-
strate that the clearance of Aβ42 is decreased in AD. Intriguingly, 
with the onset of amyloidosis, only the Aβ42 proteoform (23, 24) 
demonstrated faster turnover kinetics attributed to rapid deposi-
tion into plaques—for ~50% of all Aβ42 produced (22). Further, 
there was a positive correlation between increased Aβ42 turnover 
kinetics and rate of amyloidosis measured by PET (22). In plasma, 
the altered Aβ42 turnover kinetics and lower Aβ42/40 ratio with 
amyloidosis is also present albeit to a lesser extent (25). These 
data suggest that alterations in Aβ concentrations and kinetics 
are strongly associated with amyloidosis reflecting deposition of 
Aβ into plaques.
Longitudinal PET studies demonstrate that amyloid plaque 
pathology increases slowly and plateaus with the clinical pres-
entation of dementia (15, 20, 26–29). The slow accumulation of 
amyloid tracer binding over decades before clinical presentation 
of dementia has been suggestive of stability in plaque accumula-
tion. The plateau of amyloid tracer binding may indicate that 
amyloid pathology reaches dynamic equilibrium or quiescence 
globally at the clinical stage of dementia. Similarly, several animal 
model studies of plaques have demonstrated that plaques grow, 
typically at earlier ages (30–32), to a stable size (32–34), but that 
plaques may be in equilibrium with their environment if con-
tinual deposition is assumed (33).
However, despite the relevance of amyloid plaques in AD, 
measures of in vivo growth and distribution of human plaques 
are lacking due to analytical challenges and limitations. Previous 
human in  vivo studies (22, 25, 35) relied on CSF and plasma, 
which are indirect measures of the brain compartment and do 
not directly measure plaques. PET imaging of human brain is an 
average measure of amyloid pathology over ~1 cm, which does 
not measure individual amyloid plaques, and amyloid tracers 
bind only a subset of aggregated Aβ (36). Interpretation of PET 
results is limited because amyloid binding agents measure bind-
ing sites and not necessarily the true amount of amyloid plaques. 
Fluorescence-based assessments using multi-photon imaging of 
over-expression models, which do not fully replicate the human 
disease (37–39), encounter limitations resulting from specificity 
of dyes, decreased sensitivity due to tissue autofluorescence, and 
the inability to distinguish new versus previously existing Aβ or 
other proteins found deposited into plaques (40). As individual 
plaque dynamics have not been directly measured in humans, we 
therefore sought to measure the in vivo incorporation of protein 
into amyloid plaques to resolve whether plaques are stable or 
dynamic structures in the human AD brain.
Stable isotope labeling kinetics (SILK) was developed to deter-
mine protein production and clearance by administering a stable 
isotope labeled precursor in vivo and sampling during and after 
labeling (41). The development of SILK allowed quantitation of 
protein turnover in humans, providing a direct readout of changes 
underlying pathophysiology of disease and pharmacodynamics 
of therapeutics (22, 24, 42). However, SILK performed from CSF 
or plasma does not convey localization of labeled biomolecules in 
tissue. Nanoscale secondary ion mass spectrometry (NanoSIMS) 
allows both imaging and measurement of stable isotopes at 
high spatial resolution (50–100 nm or <1 μm3) (43, 44). While 
NanoSIMS has been applied to the study of AD (45, 46), it has 
not been used in combination with SILK for the measurement of 
in vivo protein translation in cells or deposition into plaques in 
normal or diseased brain. Here, we coupled SILK to NanoSIMS 
in a method termed SILK–SIMS to directly measure and image 
the distribution and rate of protein deposition (a proxy for growth 
taking into account area) into individual plaques at the nanom-
eter level (44, 47–49). Our aim was to measure the stability or 
growth of individual amyloid plaques in AD animal models and 
in the human brain.
Initial SILK–SIMS experiments in a mouse model of AD dem-
onstrated in vivo detection of the stable isotope tracer 13C6-leucine 
in native Aβ plaques. Further, plaques incorporated more of the 
tracer via protein deposition compared to protein translation in 
the surrounding brain parenchyma, but less than neurons. In 
human AD brain, we found 13C enrichment in multiple diffuse 
and dense-core plaques in both the frontal lobe and precuneus. 
13C enrichment was highly variable and asymmetric between 
plaques with both quiescent and active nanometer sub-regions 
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of tracer incorporation. These data reveal that human Aβ plaques 
are dynamic structures and suggest that they have growth or 
turnover rates that can be directly quantified in AD brain. Our 
results provide the first, direct measures of in vivo plaque dynam-
ics in human AD brain. We predict that SILK–SIMS will provide a 
precise understanding of protein deposition into amyloid plaques 




B-cell hybridoma line (produced in-house by Holtzman Lab, 
Washington University) was grown for 5  days in leucine-free 
media that was supplemented with either 12C6-leucine or 13C6-
leucine at 26  mg/L and mixed at the appropriate percentage 
of heavy isotope-containing media with 2% FBS. Cells were 
harvested and spun at 1,000 rpm for 5 min at room temperature 
(RT). Cell pellets were resuspended in 4°C Ringers wash solution 
for 5  min, spun, and then fixed with 4% paraformaldehyde in 
100 mM NaCl, 30 mM HEPES, 2 mM CaCl2, pH 7.2 (NaHCa) 
for 2 h. This was followed by three rinses of NaHCa at RT and 
overnight incubation at 4°C in NaHCa. Centrifugation was 
used throughout the following steps in order to re-concentrate 
the cells to a pellet. The following morning, pellets were placed 
into ddH2O and then infiltrated with LR White Embedding 
Media (Catalog #14383, EMS, Hatfield, PA) using the manu-
facturer’s published protocol with minor modification. Partial 
dehydration was accomplished by using 20% EtOH 15  min, 
40% EtOH 15 min, 50% EtOH 15 min, 70% EtOH 15 min, 85% 
EtOH 10 min, followed by 1 h in a 2:1 LR White to 85% EtOH. 
Sections of LR White embedded samples were cut on a Leica UC7 
Ultramicrotome using a diamond knife. 200  nm and 400  nm 
sections were picked up with a perfect loop, placed on top of a 
polished silicon (Si) wafer (Catalog #534, University Wafer Inc., 
South Boston, MA, USA), and let air dry on a 35°C hot plate.
animals
All animal procedures were conducted in accordance with 
the animal protocol approved by the Washington University 
Animal Studies Committee and are consistent with the National 
Institutes of Health (NIH) guidelines for the care and use of 
animals. Two male double transgenic mice expressing chimeric 
mouse/human amyloid precursor protein (Mo/HuAPP695swe) 
and a mutant human presenilin 1 (PS1-dE9) both directed to 
CNS neurons (stock 34832-JAX) (50) were kindly provided 
by Dr. Timothy Miller. Animals were given leucine-free chow 
(Catalog #1831936, Test Diet, St. Louis, MO, USA) with 5 mg/mL 
12C6-leucine added to 2% sucrose-containing drinking water to 
control leucine intake for a one-week acclimation period. After 
the 1-week acclimation period, animals were given 5  mg/mL 
13C6- or 12C6-leucine orally via 2% sucrose drinking water, averag-
ing 36 mL of H2O/week. Animals were 4 months old at the time 
of labeling (pre-plaque pathology) and 6.5 months old at the end 
of labeling (onset of plaque pathology). Following the end of the 
labeling paradigm, animals were anesthetized with 65  mg/kg 
pentobarbital sodium and sacrificed by decapitation. Brains were 
removed and placed in 10% neutral-buffer formalin (Catalog 
#15740-01, EMS, Hatfield, PA, USA). Pieces of mouse brain were 
washed into NaHCa and incubated overnight at 4°C. The follow-
ing morning, samples were stained with 1% osmium/NaHCa for 
1 h, washed four times over 1 h, and then en bloc stained with 
1% uranyl acetate/H2O for 1 h in the dark. Samples were rinsed 
with three exchanges of water, 10 min each, and then processed 
for LR White embedding as described above with the addition of 
being gold-coated once on the Si wafer. Serial adjacent sections 
were placed on glass microscope slides for toluidine blue staining 
for light microscopy.
aPP/Ps1 Plasma leucine
Mouse whole blood was spun at 1,000 × g for 10 min, and the 
plasma (supernatant) was removed. Plasma proteins were 
precipitated with ice-cold acetone followed by de-lipidation 
with hexane, and the aqueous fraction was dried in vacuo (51). 
1:1N-Methyl-N-tert-butyldimethylsilyltrifluoroacetamide/
acetonitrile was added, and samples were incubated at 70°C for 
30 min. Duplicate 1 µL injections were made into an Agilent 5973 
MSD mass spectrometer using a 30  µm × 0.25  mm DB-5MS 
column (Agilent Technologies). Electron impact ionization 
and selected ion monitoring were used to measure endogenous 
unlabeled leucine at m/z 200 (molecular ion minus C-1 as CO2-
tert-butyldimethylsilyl; CO2-tBDMS), and 13C6-leucine (tracer) 
was measured at m/z 205 as an m + 5 ion. The tracer-to-tracee 
ratio (TTR) was taken as the m +  5/m +  0 peak area ratio of 
the biological sample minus the m + 5/m + 0 ratio of a natural 
abundance leucine sample. The molar fraction of labeled leucine 
was calculated as: MFL = TTR/(1 + TTR).
human Tissue
Clinically and neuropathologically well-characterized human 
brain tissue samples were obtained from the Charles F. and 
Joanne Knight Alzheimer’s Disease Research Center (Knight 
ADRC), Washington University School of Medicine, Saint 
Louis, Missouri. At the time of death, written informed consent 
in accordance with the Declaration of Helsinki was obtained 
from the next-of-kin in accordance with the protocol approved 
by the Washington University Human Studies Committee and 
the General Clinical Research Center Advisory Committee. 
Cognitive status at expiration was determined using a validated 
retrospective post-mortem interview with an informant to 
establish the clinical dementia rating (CDR) (52). We used frozen 
tissue from the frontal lobe (Brodmann areas 8/9) of Pt2 with 
mild AD dementia (CDR 1, age at death = 88 years; post-mortem 
interval = 15 h; post-labeling interval (delta) = 8 days; Table 1). 
The right cerebral hemisphere was coronally sliced at 1 cm inter-
vals and snap frozen by contact with pre-cooled Teflon®-coated 
aluminum plates, and temperature equilibrated by immersion 
into liquid nitrogen vapor in a cryo-vessel. Following freezing, 
tissues were placed in Ziploc® storage bags and stored in freezer 
at −80°C. Participants 2 and 3 were given the stable isotope tracer 
13C6-leucine as part of previous SILK studies (22, 35). These AD 
participants had made previous arrangements for brain donation 
to Washington University.
TaBle 1 | Patient demographics for SILK-SIMS imaging of Aβ plaques.
Participant amyloid status PeT-PiB cDra aD dementia MMsea gender age Δ Between labeling and DOe (days)
1 N/A N/A N/A N/A M 59 N/Ab
2 pos 1 Mild 22 M 88 1,150 and 8c
3 pos 1 Mild 11 M 88 1,648
Clinical autopsy provided a diagnosis of Alzheimer’s disease (AD) for all participants.
CDR, clinical dementia rating; MMSE, mini mental state exam; DOE, date of expiration.
aCDR and MMSE as most recent.
bThis participant was not part of the SILK studies.
cThis participant was in two SILK studies and thus has two time lapses.
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Formalin-fixed tissue from the frontal lobe, including the 
cortical ribbon, of Pt1 (negative control, no labeling), Pt2 
(delta = 8 days), and Pt3 (delta = 4.5 years) were post-fixed in 2% 
osmium tetroxide in 0.1 M sodium cacodylate buffer for 1 h, en 
bloc stained with 3% aqueous uranyl acetate for 1 h, dehydrated in 
graded ethanols, and embeded in PolyBed 812 catalog #08792-1 
(Polysciences, Hatfield, PA, USA). Blocks were polymerized at 
80°C for 72  h. Tissue blocks were sectioned using a diamond 
ultrathin section knife on a Reichert Ultra-Cut E ultramicrotome 
at 300–500  nm. Sections were transferred to a single polished 
Si wafer for SILK–SIMS analysis. Serial adjacent sections were 
placed on glass microscope slides for toluidine blue staining for 
light microscopy. The precuneus of Pt2 was prepared and embed-
ded in LR White as described above for animal tissue along with 
samples from the 10-week labeled APP/PS1 mouse (positive 
control) and Pt1 (negative control). Serial adjacent sections were 
placed on glass microscope slides for toluidine blue staining for 
light microscopy.
light Microscopy
Toluidine blue stained sections were imaged with a Hamamatsu 
NanoZoomer 2.0-HT System. Imaging was done to guide feature 
identification and location for electron microscopy.
electron Microscopy
Images of the tissue and reference points were taken with a field 
emission scanning electron microscope (FE-SEM; QuantaTM 3D 
FEG, FEI, Hillsboro, OR, USA) in order to document plaque loca-
tions and provide an absolute coordinate system for the tissue. 
In-house coordinate transformation software was used to trans-
late tissue regions-of-interest (ROIs) and reference points found 
in the FE-SEM to the NanoSIMS instrument stage coordinate 
plane for relocation of the same ROIs. Additional sections were 
cut at 70–90  nm for transmission electron microscopy (JEOL 
JEM-1400Plus) to image selected plaques to define ultrastructure. 
Anti-Aβ antibody 82E1 (1:50; Aβ N-terminal epitope (1-16); IBL-
America, Minneapolis, MN, USA) was used with goat anti-mouse 
secondary antibody conjugated to 10 nm gold particles (1:15).
Magnetic resonance imaging (Mri)  
and PeT-PiB imaging
Participants were labeled with the radiotracer N-methyl-2-
(4-methylaminophenyl)-6-hydroxybenzothiazole (Pittsburgh 
compound B, PiB) for human brain PET imaging of amyloid 
deposition. PiB was prepared as previously described (53). PET 
and MRI were performed as previously described (54).
nanosiMs
Data were acquired on either a Cameca NanoSIMS 50 at 
Washington University (cells and human tissue) or NanoSIMS 
50 L at Brigham and Women’s Hospital (mouse tissue). Images of 
the B-cell hybridoma used to calculate the 13C6-leucine standard 
curve were acquired with a 50 µm primary beam raster for 15 min 
at 1 ms/px and 65.5 s/plane (dwell time) for a total of 10 planes 
(i.e., cycles) per mass (256 × 256 px). APP/PS1 mouse brain tissue 
was acquired at a 17–60 µm raster for 11–87 min at 2 ms/px and 
131 s/plane (dwell time) for a total of 5–40 cycles (i.e., planes) 
per mass (256 ×  256 px). For all APP/PS1 measurements, the 
non-labeled cells (0%) were measured prior to the SILK–SIMS 
data acquisition. The unlabeled cells and the natural abundance 
of carbon-13 (55) were used for quantitation of normalized 
ratios for mouse plaques and neuron. Plaque ROI outlines were 
drawn based on plaque morphology and areas around the plaque 
defined such they do not overlap or intersect with the predefined 
plaque ROIs.
The human tissue was analyzed in three sets. In the first set 
(frontal lobe), Pt1 (negative control) and Pt2 frontal lobe were 
embedded in PolyBed 812 and pre-sputtered using the D1-1 
aperture for 10 min followed by data acquisition at a raster size 
between 35 and 50 µm raster with a D1-2 aperture. Data acquisi-
tion was 4  h at 5  ms/px and 327.68  s/plane (dwell time) for a 
total of 40 planes (i.e., cycles) per mass (256 × 256 px). In the 
second set (precuneus), Pt2 precuneus samples (embedded in 
LR White; Figures S9 and S11 in Supplementary Material) were 
pre-sputtered at 30 µm raster with a D1-1 aperture for 10 min fol-
lowed by data acquisition at 25 µm raster with the D1-2 aperture. 
Data acquisition was 2.5 h at 5 ms/px and 327.68 s/plane (dwell 
time) for a total of 25 planes (i.e., cycles) per mass (256 × 256 
px). Pt1, also embedded in LR White, was used as the negative 
control in this experimental set. Finally, unlabeled AD tissue 
(Pt1; in Supplementary Material) embedded in PolyBed812 was 
acquired with a 45 µm raster for 11.6 h at 4 ms/px and 1,048.576 s/
plane (dwell time) for a total of 40 planes (i.e., cycles) per mass 
(512 ×  512 px). Pt3’s (in Supplementary Material) brain tissue 
was acquired with a 55 µm raster for 18 h at 5 ms/px and 1,310 s/
plane (dwell time) for a total of 40 planes (i.e., cycles) per mass 
(512 × 512 px). For all measurements, the non-labeled material 
(Pt1) was measured prior to the SILK–SIMS data acquisition. 
In this way, the negative control data were acquired first before 
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SILK data acquisition, and the electron multipliers were no longer 
adjusted after negative control data were acquired.
nanosiMs Data analysis
Each analysis was performed in 24-h blocks with measurements 
on a SiC standard of known isotopic composition to assess 
instrument stability followed by measurements on an unlabeled 
control prior to SILK–SIMS data acquisition. Raw image data 
were imported into the L’Image image processing software (Larry 
Nittler, Carnegie Institution of Washington) to produce quantita-
tive ratio images of heavy and light isotopes and determine where 
isotopic anomalies were located. Images were automatically 
segmented into 10 × 10 pixel ROIs using L’image, and the heavy/
light isotopic ratios were calculated from the summed ion counts 
within each ROI. The fractional uncertainty, ƒ, of each ROI ratio 
heavy/light isotope ratios in each region-of-interest (ROI) was 
calculated in Excel as the sum in quadrature of the standard 
deviation of the average ratios measured for non-labeled mate-
























where RStd is the average ratio of repeated measurements on 
unlabeled tissue, and RROI is the ratio calculated from summing 
the counts of every pixel contained within the individually 
defined ROI. This uncertainty represents the entire experimental 
precision and accuracy, including: counting statistics, matrix 
effects, systematic error, instrumental tuning, and differences 
between standards and samples. From this uncertainty, the 
amount, significance, and location of heavy isotopic labeling 
can be quantitatively determined. Those ROIs with heavy/light 
isotope ratios greater than or equal to the μ + 2σ value of the 
unlabeled sample were analyzed by a one-sample t-test. Two SDs 
from the mean (2σ) was chosen to ensure high confidence in 
isotope enrichment (i.e., 95%) prior to the one-sample t-test; by 
analogy in the field of Physics, a minimum 5σ effect is required 
for statistical confidence. Each t-value of the resulting t-tests 
was corrected for multiple testing with a FDR of 0.01 using the 
Benjamini-Hochberg method (56). Those ROIs which remained 
significant after correcting for multiple comparisons remain 
outlined in the images.
aβ extraction
1 g of frontal lobe tissue was homogenized in ice-cold 1X PBS 
with 0.05% CHAPS and centrifuged at 17,000 × g for 30 min at 
4°C as previously described (57). The supernatant was spun for 
1 h at 100,000 × g at 4°C, and the resulting pellet was solubilized 
in 5 M guanidine overnight at 4°C with rotation. Next, samples 
were spun for 20 min at 17,000 × g at 4°C, and the supernatant 
was diluted 1:10 in 1X PBS in BSA-block tubes as previously 
described (57). Samples were immunoprecipitated (IP) with 50 
μL of HJ5.1 anti-Aβ antibody [mid-domain epitope (17–28)] 
coupled Dynabeads (Catalog #14311D, Invitrogen, Carlsbad, 
CA, USA) made following the manufacturer’s instructions. After 
overnight incubation at 4°C, IPs were eluted in neat formic acid 
and dried in vacuo. Samples were resuspended in 50 mM TEABC 
(Catalog #17902, Sigma, St. Louis, MO, USA), spiked with 15N-
Aβ internal standard, and digested overnight with 0.25  ng/µL 
Lys-N (Catalog #100965-1, Seikagaku Biobusiness Corp., Tokyo, 
Japan) at 4°C.
Mass spectrometry
Samples were resuspended in 1% FA/10% ACN (v/v) with 20 nM 
BSA digest (Catalog #1863078, Pierce, Rockford, IL, USA). 
Samples were analyzed in triplicate by nanoLC-MS/MS on an 
LTQ-Orbitrap Fusion (Thermo Fisher Scientific) in positive ion 
mode. Separations were performed using an online NanoAcquity 
UPLC (Waters, Milford, MA, USA) using an ACQUITY UPLC 
HSS T3 (360 µm OD × 75 µm ID) column packed with 10 cm 
C18 (1.8 µm, 100 Å, Waters) at 300 nL/min and heated to 65°C. 
Mobile phases were 0.1% FA in water (A) and 0.1% FA in ACN 
(B). Samples were eluted from the column with the gradient 
starting at 12% B, which was ramped to 32% B over 10 min and 
further increased to 90% B over 5 min and held for 1 min, before 
re-equilibration to 12% B over 2 min. Total run time, including 
column equilibration, sample loading, and analysis, was 30 min. 
The mass spectrometer was operated in targeted MS2 mode. 
MS2 spectra were acquired in the Orbitrap (30,000 at m/z 400) 
in centroid mode using XCalibur, version 4.0 (Thermo Fisher 
Scientific). Ion injection times for the targeted MS2 scans for 
labeled and unlabeled samples, respectively (in ms) were: Aβ 
mid-domain (54, 1080), Aβ40 (54, 540), and Aβ42 (54, 1080). The 
Orbitrap automatic gain control targets were set to 5 × 105 for all 
proteoforms except Aβ42, which was set to 1 × 106. The targeted 
precursor ions were sequentially isolated in the quadrupole and 
fragmented in the Orbitrap using HCD (isolation width 1.6 Da, 
normalized collision energy 25%, activation Q 0.250, and activa-
tion time 10 ms). The general mass spectrometric conditions were 
as follows: spray voltage 2.2 kV, 60% S-lens, and ion transfer tube 
temperature 275°C.
Mass spectrometry Data analysis
Data (.raw files) were imported into a Skyline template contain-
ing the Lys-N C-terminal peptides of Aβ38, 40, 42, and the mid-
domain. Retention time alignment was based on the 15N internal 
standard. The sum of all transitions (b ions monitored for each 
parent peptide) for unlabeled and 13C6-leucine labeled Aβ pep-
tides were exported from Skyline to Excel. The ratios of labeled/
unlabeled of each replicate (triplicate injections) for Pt2 sample 
were taken followed by isotopic background subtraction of the 
mean ratio of an unlabeled participant to give the TTR minus 
background for each replicate injection. Next, the background 
subtracted TTRs were used to calculate the mean and SD (i.e., 
the mean of the area ratios) of enrichment for each Aβ peptide.
Data availability statement
NanoSIMS image files (.im) and L’Image saved session (.sav) files 
are available upon request from corresponding authors. Excel 
data analysis files for human NanoSIMS images can be found in 
the Supplementary Material.
FigUre 1 | SILK-SIMS dose response curve for 13C6-leucine enrichment. B-cell hybridoma cells were labeled with increasing percentages of 13C6-leucine. The 
standard curve demonstrates a monotonic relationship between detected 13C14N/12C14N and the percent 13C6-leucine enrichment in cell media. Red line represents 
the mean of 13C14N/12C14N ± SD of the regions-of-interest outlined in (Figure S3 in Supplementary Material). The blue line represents the normalized mean 
13C14N/12C14N ± SD. Each standard curve point was normalized (Equation 4 in Supplementary Material) to the ratio of natural abundance 13C and unlabeled cells 
(0%). The normalized SD was calculated as the sum in quadrature of the SD of the average ratios measured for non-labeled cells (0%) and the Poisson errors of the 
feature itself (Equation 5 in Supplementary Material). Note the expected intercept at ~1.1%. Inset: enlarged view of the three lowest points on the dose-response 
curve. Enrichments as low as 1.25% were detectible above background. Dashed horizontal line represents natural abundance of 13C (1.1%).
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resUlTs
Quantification of 13c and In Vivo labeling
To quantify carbon isotopes in biological material, we measured 
carbon as negative ions of 12C, 13C, 12C14N, and 13C14N. Using a 
B-cell hybridoma grown in leucine-free media supplemented 
with increasing percentages of 13C6-leucine, we characterized the 
signal response for 13C enrichment. Figure 1 demonstrates the 
linearity of response of SILK–SIMS measurements to increasing 
isotopic enrichment of 13C6-leucine in culture measured as the 
ratio of 13C14N/12C14N, which produced improved image quality 
and more accurate quantification (Figure S1–3 in Supplementary 
Material). To determine whether 13C6-leucine enrichment could 
be detected in vivo in native Aβ plaques, two individual APP/PS1 
mice (3.5 months of age) were administered 13C6-leucine tracer 
for 10 and 5 weeks (Figure 2A). The mouse labeled for 10 weeks 
(Figure  2B) reached a 13C14N/12C14N ratio of 2.4% ±  0.03% in 
plaque (expected unlabeled at 1.1% due to 13C natural abundance) 
compared to brain parenchyma (2.2% ± 0.03%) in both Area 1 
and Area 2 (Figure 2B; Figure S4 in Supplementary Material). 
A plaque from the APP/PS1 mouse labeled for 5 weeks, followed 
by a 5-week washout, remained enriched at 1.6% ± 0.02% rela-
tive to natural abundance (Figure 2C), and compared to adjacent 
areas (1.4% ± 0.02%). Despite being labeled for half the amount 
of time with an additional 5 weeks of tracer washout, the plaque 
enrichment was approximately two-thirds of that measured in the 
10-week labeled animal (1.6% ±  0.02% vs. 2.4% ±  0.03%). The 
enrichment of plasma leucine measurements taken at the time of 
collection was fourfold lower (72 vs. 16% isotopically labeled leu-
cine in the 10-week vs. 5-week labeled mouse, Table 1). A neuron 
incorporated substantially more tracer than the surrounding 
parenchyma (neuron = 3.3% ± 0.05% vs. area 1 = 2.4% ± 0.03% vs. 
area 2 = 2.4% ± 0.03%) and the plaque (Figure S5 in Supplementary 
Material) in the 10-week labeled mouse. These results demon-
strate that 13C6-leucine incorporation into Aβ plaques and other 
features could be measured and is localized to protein deposition 
(i.e., plaques) and protein translation (i.e., cells).
In Vivo labeling and Quantification  
of human aD Plaques
The APP/PS1 mouse model (50) is an over-expression model of 
APP mutations typically found in early onset, familial disease, 
which accounts for <1% of AD cases (58) and does not replicate 
all aspects of the human disease or human amyloid-plaques 
(37–39). Further, despite intensive study of plaque dynamics in 
animal models (30–34), little is known about individual plaque 
dynamics in human AD brain. The demonstrated feasibility 
of measuring 13C6-leucine incorporation in native Aβ plaques 
from mouse brain (Figure 2) prompted us to investigate post-
mortem tissue from previous SILK study participants (22, 35). 
Plaques from unlabeled AD participant tissue (Table 2; Figure 
S6 in Supplementary Material) were similar to the natural 
abundance of 13C as expected. In a previous SILK participant 
(Pt3) (22), who had a post-labeling interval of 4.5 years (Figure 
S7 in Supplementary Material), we were also unable to detect 
13C enrichment in the examined areas. In contrast, post-mortem 
tissue from Pt2, who was labeled (35) and passed away 8 days 
later due to an unrelated cause, had significant 13C enrichment 
in amyloid plaques (Figure  3). Four diffuse plaques in the 
FigUre 2 | Stable isotope incorporation within plaques of APP/PS1 mouse model of Alzheimer’s disease. (a) Labeling scheme to determine the feasibility of 
detecting in vivo incorporation of stable isotope 13C in native Aβ plaques. (B,c) From left to right, 12C14N ion map, 13C14N ion map, 13C14N/12C14N ion map, and 
normalized 13C14N/12C14N ratios of 10-week and 5-week labeled APP/PS1 mice, respectively (35 × 35 μm images; see, Figure S4 in Supplementary Material, for 
region-of-interest (ROI) outlines based on plaque morphology and areas around the plaque defined such they do not overlap with plaque ROIs). Error bars 
indicate ± SD in quadrature of the SD of the average ratios measured for non-labeled cells (0%) and the Poisson errors of the feature itself (Equation 5 in 
Supplementary Material). Dashed horizontal line represents natural abundance of 13C (1.1%). Scale bar, 2 µm.
TaBle 2 | Plasma leucine in labeled APP/PS1 mice.
12c6-leucine peak area 13c6-leucine peak area 13c/12c TTr Mol fraction labeled average Mol fraction labeled
10 week 4,579 11,793 258% 258% 72% 72%
4,601 11,845 257% 257% 72%
5 week 14,438 2,878 20% 20% 16% 16%
14,256 2,724 19% 19% 16%
Each sample was injected twice with excellent reproducibility.
TTR, tracer-to-tracee ratio.
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frontal lobe displayed puncta of 13C labeling intercalated in the 
periphery and fibrillar interior (Figure  3C). Notably, not all 
plaques demonstrated equivalent amounts of 13C incorporation 
or the same number of enriched regions (max 13C = 1.26, 1.34, 
1.49, and 1.20%, for plaques 1–4, respectively). Among plaques 
with an equivalent number of enriched regions (e.g., plaques 
2 and 3) 13C enrichment varied, suggesting differing rates of 
13C incorporation among “dynamic” plaques (Figures  3C,D). 
Additionally, the number of areas with significant enrichment 
drastically differed, indicating that plaque incorporation of 13C 
is highly asymmetric and can be constrained to specific regions 
or sub-regions; in the case of plaque 4, it is confined to a 3.0 µm2 
area (Figures 3C,D; Figure S8 in Supplementary Material). To 
confirm this result was not restricted to a single brain region, we 
examined plaques in the precuneus (Figure S9 in Supplementary 
Material). Of the two dense-core plaques imaged by SILK–SIMS 
and verified by immunoelectron microscopy (Figure S10 in 
Supplementary Material), only plaque 5 had 13C enrichment 
within the plaque, the peri-plaque region (Figures S9A–F in 
Supplementary Material), and up to 50 µm away (Figure S11 in 
Supplementary Material). In contrast, plaque 6 had a low num-
ber of enriched regions, which appear part of the surrounding 
brain parenchyma (Figures S9G–L in Supplementary Material) 
rather than the plaque itself, suggesting a quiescent plaque. To 
FigUre 3 |  In vivo stable isotope incorporation of 13C within plaques in the frontal lobe of clinically and pathologically confirmed Alzheimer’s disease brain.  
(a) Primary question: are amyloid-β plaques dynamic structures able to incorporate the stable isotope tracer 13C6-leucine and can this be directly measured in the 
human brain? (B) Traditional imaging of SILK Pt2 by T2-weighted magnetic resonance imaging (MRI) (upper) and by PET-PiB (lower) in a coronal view. Hippocampal 
atrophy (red) in the MRI image is apparent along with prominent PiB binding in the PET image. SUVR, standardized uptake value ratio. (c) Four diffuse plaques in 
the frontal lobe of SILK Pt2 and a dense core plaque from the frontal lobe of non-SILK Pt1 (Table 2). From left to right, scanning electron microscope (SEM) image 
of the plaque (red box defines area imaged by SILK–SIMS), 12C14N ion map, 13C14N ion map, and 13C14N/12C14N ion map. (D) Summary scatter plot of all plaque 
region-of-interest normalized ratios shown below. Horizontal bars represent plaque 13C14N/12C14N medians, and dashed horizontal line represents natural abundance 
of 13C (1.1%). Scale bar for all SEM images, 40 µm. Scale bar for all SILK–SIMS images, 5 µm. SEM magnification and SILK–SIMS image raster, respectively: Plaque 
1: 636X and 25 × 25 μm; Plaque 2: 1,024 and 35 × 35 μm; Plaque 3: 628X and 50 × 50 μm; Plaque 4: 628X and 45 × 45 μm; NegControl: 600X and 45 × 45 μm.
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provide orthogonal validation of the presence of 13C6-leucine 
Aβ proteoforms (23) in Pt2 brain, we used targeted nLC-MS/
MS. In Aβ from insoluble aggregates (57), we quantified 13C6-
leucine labeled Aβx-40, 42, and mid-domain peptides, which 
were enriched at relative abundances of 0.112, 0.022, and 0.053% 
above natural abundance, respectively, while Aβx-38 was not 
detected as expected (Figure 4).
DiscUssiOn
In the current study, we utilized brain tissue from participants 
enrolled in previous SILK studies (22, 35) for NanoSIMS imaging. 
During the in vivo stable isotope labeling procedure (41) newly 
synthesized proteins are labeled simultaneously. As a result, many 
different features (e.g., plaques, parenchyma, and neurons) and 
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FigUre 4 | Continued
FigUre 4 | Targeted nLC-MS/MS of Aβ proteoforms from an insoluble fraction of SILK Pt2. Extracted ion chromatograms (XIC) are shown for (a) Aβ mid-domain, 
(B) Aβx-40, and (c) Aβx-42 in Pt2 (8 day delta between labeling and expiration) of unlabeled Aβ and 13C6-leucine labeled (SILK), respectively. (D) The average of each 
tracer-to-tracee ratio (TTR) from triplicate injections using targeted nLC-MS/MS after background subtraction from an unlabeled participant sample. The relative 
quantitation of Aβ mid-domain, Aβx-40, and Aβx-42 provides additional evidence of 13C6-leucine present in the brain even after supposed label washout. Error bars 
represent ± SD.
10
Wildburger et al. Plaque Dynamics and Heterogeneity in AD
Frontiers in Neurology | www.frontiersin.org March 2018 | Volume 9 | Article 169
kinetic processes (e.g., protein translation, transport, deposi-
tion, and clearance) in the brain can be imaged directly without 
the reliance of analytical intermediaries or modifications such as 
fluorescence. In the previous SILK studies, 13C6-leucine was used 
as the tracer (41, 59). However, in SILK-SIMS, 13C is isotopically 
diluted, decreasing sensitivity, due to the abundance of carbon 
in mammalian tissues and the carbon-based embedding media. 
As a result, we were only able to successfully detect 13C enrich-
ment in one participant who had a post-labeling interval of eight 
days. Yet, to the best of our knowledge, this represents the first 
report of imaging of individual human amyloid plaques in vivo 
dynamics at the nanometer scale not appreciable by previous 
methods.
human aβ Plaques are Dynamic 
structures
The incorporation of 13C6-leucine into plaques (i.e., protein 
deposition) in a participant with clinical stage AD dementia sug-
gests that plaques can be dynamic with activity over days even in 
later stages of the disease. Notably, we were able to demonstrate 
dynamic activity in both diffuse and dense-core plaques in 
contrast to previous animal model studies (30–34), which were 
restricted to imaging dense-core plaques due to the use of fluo-
rescent plaque binding reagents Thioflavin S and Methoxy-04. 
The “activity” of individual plaques can be highly variable as 
demonstrated by varying isotope enrichment, suggesting differ-
ing rates of protein incorporation even among individual plaques 
in the same brain region. A single plaque could simultaneously 
demonstrate nanometer scale regions of dynamic incorporation 
of the tracer as well as quiescence—highly asymmetric tracer 
incorporation.
Plaque asymmetry was previously suggested (33) in a mouse 
model of AD but was attributed to asymmetrical clearance. The 
quiescence regions and sub-regions of individual plaques could 
be interpreted as either asymmetric clearance or differential 
nanometer scale deposition. However, not all plaques incorpo-
rated the tracer indicating a lack of protein deposition during the 
same timeframe. Together, these results demonstrate that plaques 
can be at both dynamic equilibrium and quiescence within a sin-
gle participant even with dementia, at both the individual plaque 
level and plaque nanometer sub-region level, despite PET studies 
suggesting no net change (20, 26–29).
relationship to Previous studies  
and limitations
Previous visualizations of plaque formation examined by multi-
photon imaging have arrived at differing conclusions (30–34). This 
may be due to a potential significant impact on plaque response 
with surgical intervention and the use of over-expression models 
versus direct human pathophysiology. Multi-photon imaging has 
the advantages of visualization of individual plaques over time in 
the same animal non-destructively albeit at lower resolution limit 
compared to SILK–SIMS. In contrast, SILK–SIMS is a destruc-
tive technique where the isotope profiles are obtained at the 
expense of the molecular identities of the newly synthesized and 
deposited biomolecules. This is particularly relevant as plaques 
are heterogeneous structures containing other proteins, cellular 
debris, and lipids (40), which may contribute to the 13C signal 
seen in the SILK-SIMS images. As Aβ is the main constituent of 
plaques, we validated 13C enrichment by nLC-MS/MS from the 
same sample in an orthogonal manner. This orthogonal measure 
can be applied to other proteins of interest (e.g., alpha-synuclein, 
tau, and prion protein), or MALDI imaging (60, 61) may be used 
in parallel to obtain molecular identities of plaque constituents 
in situ, though at micrometer resolution.
cOnclUsiOn anD OUTlOOK
The application of SILK–SIMS to future studies will allow 
estimates of the rate and distribution of plaque deposition at 
the nanometer level across human AD cohorts. The results will 
provide a better understanding of the rate of AD pathophysiol-
ogy and may have a significant impact on the development of 
therapeutic strategies; for example, drugs targeting amyloid 
plaque growth and resorption through a variety of mechanisms. 
However, SILK–SIMS, unlike PET imaging, is currently limited 
to post-mortem tissue. Biopsies are an alternative but are invasive 
and only feasible with surgery to relieve other conditions such as 
normal pressure hydrocephalus. Nonetheless, SILK–SIMS may 
also be applied to measuring other proteinaceous deposits such 
as Lewy bodies (alpha-synuclein), neurofibrillary tangles (tau), 
and prion protein, which are characteristic of Parkinson’s disease, 
frontotemporal dementia and AD, and Creutzfeldt–Jakob disease, 
respectively. In general, the SILK–SIMS approach can be used to 
visualize incorporation of new biomolecules at the nanometer 
scale to measure growth and turnover to better understand physi-
ology and pathophysiology of many disease states, neurological 
and non-neurological.
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